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Abstract
The large‐scale production and isolation of recombinant protein is a central element
of the biotechnology industry and many of the products have proved extremely
beneficial for therapeutic medicine. Escherichia coli is the microorganism of choice for
the expression of heterologous proteins for therapeutic application, and a range of
high‐value proteins have been targeted to the periplasm using the well characterized
Sec protein export pathway. More recently, the ability of the second mainstream
protein export system, the twin‐arginine translocase, to transport fully‐folded
proteins into the periplasm of not only E. coli, but also other Gram‐negative bacteria,
has captured the interest of the biotechnology industry.
In this study, we have used a novel approach to block the export of a heterologous Tat
substrate in the later stages of the export process, and thereby generate a single‐span
membrane protein with the soluble domain positioned on the periplasmic side of the
inner membrane. Biochemical and immuno‐electron microscopy approaches were used
to investigate the export of human growth hormone by the twin‐arginine translocase,
and the generation of a single‐span membrane‐embedded variant. This is the first time
that a bonafide biotechnologically relevant protein has been exported by this
machinery and visualized directly in this manner. The data presented here demonstrate
a novel method for the production of single‐span membrane proteins in E. coli.
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1 | INTRODUCTION
Escherichia coli is responsible for the production of over one‐third of
therapeutic proteins (Walsh, 2010). Conventional strategies for the
isolation of these heterologous, recombinant proteins from E. coli
include, expression of soluble proteins in the cytoplasm, expression
as insoluble inclusion bodies, or export to the periplasm with
subsequent outer membrane rupture to release the periplasmic
contents (Pooley, Merchante, & Karamata, 1996). Adoption of the
latter approach offers two main advantages: First, the oxidizing
environment of the periplasm allows disulfide bonds to form, and
second, rupturing of only the outer membrane of Gram‐negative
bacteria means there are fewer contaminating cytoplasmic proteins.
The ability of the twin‐arginine translocase (hereafter denoted Tat
system) to transport fully‐folded proteins into the periplasm of Gram‐
negative bacteria is valued by the biotechnology industry for its potential
to simplify the downstream processing of high‐value, biotherapeutic
proteins. Initial studies investigated the ability of the Tat translocase to
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transport a model heterologous protein on a large scale. These studies
showed that Tat could export green fluorescent protein (GFP) at levels
comparable with conventional methods, and with no large‐scale release
of cytoplasmic contents (Matos et al., 2012), confirming this machinery's
potential as a viable method for producing heterologous protein.
Most of the Tat system's substrates are soluble proteins, and most
studies on the biotechnological exploitation of the system have similarly
focused on soluble high‐value protein (Alanen et al., 2015; Browning
et al., 2017; Matos et al., 2013). However, the Tat system does have
considerable potential for the production of single‐span heterologous
membrane proteins, particularly those that contain a globular domain
located on the periplasmic face of the inner membrane. Two studies
have shown that it is possible to “stall” a Tat substrate at the inner
membrane by virtue of a substitution mutation in the signal peptidase
cleavage site of a TorA signal peptide (Karlsson et al., 2012; Ren, Patel,
& Robinson, 2013). Both studies used biochemical approaches to
demonstrate that a Tat substrate remained membrane‐anchored with
its mature domain exposed at the periplasmic side of the inner
membrane. These data reveal a potential for the Tat translocase to be
used in the production of membrane‐bound proteins or for bacterial cell
surface display technologies.
Bacterial surface display involves the presentation of a recombinant
protein or peptide on the surface of microorganisms, most common of
which is E. coli, owing to its ease of genetic manipulation and ability to
produce recombinant proteins in high yields. As the name suggests, this
presentation technology results in the protein of interest being
positioned on the surface of the cell where it is available for interaction
with any externally added substrate, which does not have to penetrate
the membrane. Implementation of this technique has proven beneficial
for numerous applications, including biofuel production and protein
library screening (Wu, Mulchandani, & Chen, 2008).
A prerequisite of cell surface display in E. coli is that the protein of
interest is successfully transported across the inner membrane and
into the outer membrane; however, the presence of lipopolysacchar-
ides can sterically hinder interactions between expressed protein and
binding partner, and assembly at cellular appendages (e.g., flagella or
pilli) can disrupt assembly of the recombinant protein (Chen &
Georgiou, 2002). Therefore, alternative methods are required that
avoid the pitfalls of displaying a protein at the outer membrane. An
anchored periplasmic expression is one such alternative that involves
the display of heterologous protein in the periplasm of E. coli, which is
tethered to the inner membrane by a lipoprotein targeting motif
(Mazor, Van Blarcom, Iverson, & Georgiou, 2008).
The vast majority of proteins that are presented using this method
are exported out of the cytoplasm in an unfolded state via the Sec
translocon (Driessen & Nouwen, 2008). However, this export is reliant on
the recombinant protein refolding to a native, biologically active
conformation in the periplasm. Use of Tat machinery to traverse the
inner membrane avoids this issue, since this machinery contains an
inherent quality control mechanism that only allows soluble, correctly
folded proteins to be transported from the E. coli cytoplasm, across the
inner membrane, and into the periplasm (DeLisa, Tullman, & Georgiou,
2003; Fisher, Kim, & DeLisa, 2006). Whereas inner membrane display
does require outer membrane removal to gain access to the recombinant
protein, in instances where cell surface display on the outer membrane of
bacteria is impossible, or hugely inefficient, this “extra‐step” of membrane
removal far outweighs the difficulty of displaying protein at the outer
membrane. Such an approach has previously been used when displaying
scFVs via Tat machinery (Karlsson et al., 2012; Moghaddam‐Taaheri,
Ikonomova, Gong, Wisniewski, & Karlsson, 2016).
This inherent quality control mechanism of the Tat machinery, in
combination with data showing that a signal peptide mutation in a
Tat substrate is able to stall a Tat precursor at the inner membrane
(Ren et al., 2013), highlights the potential for Tat machinery in cell
surface display technology.
To investigate this further, we used biochemical and electron
microscopy approaches to analyze the export of a biopharmaceutical,
human growth hormone (hGH), which has been shown to be
successfully transported by the Tat machinery (Alanen et al., 2015).
hGH is a single polypeptide chain of 191 amino acids and is one of the
most important hormones in the human body, possessing vital roles
in numerous biological processes including cell metabolism and
proliferation (Kassem, Blum, Ristelli, Mosekilde, & Eriksen, 1993).
Recombinant hGH is used therapeutically to treat hGH deficiency
and a range of genetic disorders (Sanchez‐Ortiga, Klibanski, & Tritos,
2012; Spiliotis, 2008; Takeda et al., 2010; Vogt & Emerick, 2015).
Only two heterologous proteins have been shown to be anchored
in the cell envelope of E. coli via the Tat machinery. Maltose binding
protein (MBP) was anchored at the inner membrane via the addition
of a 22‐residue C‐terminal transmembrane helix (from the native Tat
substrate, HybO; Karlsson et al., 2012). The same study also detected
scFv13 (human antibody fragment specific for ß‐galactosidase) at the
inner membrane when a FLAG tag was positioned between the signal
peptide and the scFv domain.
In this study, we have sought to achieve stable expression of a
noncleavable Tat precursor at the inner membrane of E. coli with no
alterations to the mature protein, and we have used immunogold
electron microscopy to precisely localize the target proteins for the
first time.
Direct immunogold labeling revealed that overexpressed, mem-
brane‐targeted hGH exhibits a uniform distribution in the inner
membrane of E. coli. The data confirm that this type of approach can be
used for the display of globular protein domains on the periplasmic
face of the inner membrane.
2 | MATERIALS AND METHODS
2.1 | Export assays of hGH in E. coli cells
E. coli cells (transformed with a plasmid containing either wild‐type
(WT) or mutant precursor hGH (Alanen et al., 2015), were cultured in
1 L Luria Broth (LB) media and induced with 1mM arabinose (or
1mM isopropyl β‐D‐1‐thiogalactopyranoside [IPTG]) and cultured for
2 hr. At given intervals (0 hr, 1 hr, 1 hr 15min, 1 hr 30min, 1 hr
45min, and 2 hr), 10ml of culture was harvested and the cell pellet
was normalized against an optical density of 600 nm (e.g., for an
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optical density of 0.6 at 600 nm, the cell pellet was resuspended in
0.6 ml of disruption buffer [100mM Tris‐acetate pH 8.2, 500mM
sucrose, and 5mM ethylenediaminetetraacetic acid {EDTA}]).
2.2 | Fractionation of E. coli cells and detection of
hGH protein
E. coli cells were fractionated into periplasmic, cytoplasmic, and
membrane fractions using the lysozyme/cold osmotic shock method
(Randall & Hardy, 1986). The resulting fractions were analyzed by
sodium dodecyl sulfate‐polyacrylamide gel electrophoresis (SDS‐PAGE).
Once the periplasmic, cytosolic, membrane, and insoluble samples
had been analyzed using SDS‐PAGE, the proteins were transferred from
acrylamide gels to polyvinylidene difluoride (PVDF) membranes via
semi‐dry western blot analysis apparatus. The membranes were blocked
overnight in a solution of 5% (w/v) dried milk in phosphate‐buffered
saline (PBS)‐Tween [0.8% NaCl (w/v), 0.02% KCl (w/v), 0.144%
Na2HPO4 (w/v), 0.024% KH2PO4 (w/v), and 0.2% Tween‐20 (v/v), pH
7.2] and then incubated with primary anti‐hGH antibody (1:20,000, Tris‐
buffered saline (TBS)/Tween [0.24% Tris (w/v), 2.5% NaCl (w/v), and
0.2% Tween‐20 (v/v), pH 8.4]) for 1 hr before washing. Membranes
were incubated with anti‐rabbit‐horseradish peroxidase (HRP) con-
jugate (Promega, WI) for 1 hr at room temperature (RT), and
subsequently washed. Finally, immunoreactive bands were detected
using ECLTM detection reagents according to the manufacturer's
instructions. X‐ray films were developed using an AGFA Curix 60
automatic developer as directed by the manufacturer's instructions.
2.3 | Fractionation of E. coli cells and detection of
LacI and maltose binding protein
The detection of LacI and maltose binding protein in E. coli cells was
conducted as described in Section 2.2, with the only difference being
the primary antibody used. To detect LacI and maltose binding
protein, anti‐LacI and anti‐maltose binding protein primary anti-
bodies were used (both at 1:20,000, TBS/Tween [0.24% Tris (w/v),
2.5% NaCl (w/v), and 0.2% Tween‐20 (v/v), pH 8.4]), respectively.
2.4 | Preparation of E. coli cells for visualization by
electron microscopy
Chemical fixation of E. coli cells: E. coli cells (overexpressing eitherWT or
mutant precursor hGH) were resuspended in aldehyde fixative (0.25%
glutaraldehyde/4% formaldehyde) and low‐melting temperature agar-
ose at 1:1 volume ratio. Agarose‐enrobed cells were then harvested and
incubated on ice until the agarose had set. Cells were diced into 1mm3
pieces using a clean razor blade and resuspended in fresh aldehyde
fixative for overnight fixation at 4°C. Chemically fixed cells were
washed for 1–2 hr in 0.15M sodium cacodylate/HCl buffer pH 7.4 at 4°
C to remove aldehyde fixative. The reaction was then quenched for 1 hr
by washing in cacodylate buffer containing 0.1M glycine. A contrast
was imparted to the cells by incubation in 1% tannic acid (TA) for 1 hr at
4°C, followed by washing in H2O for the second staining of 1% uranyl
acetate (aq) for 1 hr at 4°C. E. coli cells were dehydrated in an ethanol
series (70–100%) for a period of 2 hr for subsequent resin embedding
(London Resin Company Ltd., Berkshire, UK).
2.5 | Ultrathin sectioning of resin blocks for
imaging by transmission electron microscopy
Ultrathin (50 nm) sections were cut (using an ultramicrotome
[Ultracut E, Reichert‐Jung; Vienna, Austria]) and transferred to
200‐mesh carbon‐coated copper grids (Agar Scientific, Stansted
Essex) for immunolabelling of hGH (Section 2.5) and subsequent
transmission electron microscopy (TEM) imaging.
2.6 | Immunolabelling of E. coli cells to detect hGH
in the inner membrane
Using the touching‐drop method (Rubinstein, 2007), ultrathin
sections were blocked via incubation in TBS/Tween buffer (0.24%
Tris (w/v), 2.5% NaCl (w/v), and 2% Tween‐20 (v/v)) pH 8.4
containing 1% BSA (w/v) and 4% normal goat sera (v/v) (Abcam
Plc, Cambridge, UK) for 30min at RT. hGH protein was labeled by
incubation with primary anti‐hGH antibody (rabbit polyclonal) at
1:20,000 dilution (TBS/Tween + 1% BSA buffer) for 2 hr at RT.
Sections were then washed with TBS/Tween + 1% BSA at RT and
then incubated with 10 nm gold‐conjugated secondary antibody
(Goat antirabbit IgG pre‐adsorbed, Abcam Plc) for 1 hr at RT. Finally,
sections were washed in TBS/Tween ( + 1% BSA) and dH2O and
allowed to air dry before insertion into the electron microscope (EM).
2.7 | Transmission electron microscopy of ultrathin
E. coli sections
Ultrathin sections of E. coli cells were imaged under a 200 kV JEOL
2010F transmission electron microscope with a field emission gun
electron source, operating a Gatan Ultrascan™ 4000 CCD camera
with a pixel size of 14 μm.
2.8 | Quantification of immunogold labeling
A random sampling approach was used to analyze the distribution of
gold within the immunolabelled E. coli sections, as in [Smith et al.,
2017]. An identical Chi‐squared analysis procedure (as in [Smith
et al., 2017]) was performed on samples of E. coli cells overexpressing
either WT or mutant precursor hGH, with the null hypothesis (of no
difference in immunolabelling between hGH‐overexpressing cells and
WT E. coli cells not overexpressing any recombinant protein) being
rejected (p < 0.005).
2.9 | Time profile of cell growth of E. coli cells
overexpressing TorA‐hGH and TorA‐A39L‐hGH
Growth curves of TorA‐hGH and TorA‐A39L‐hGH were generated by
growing E. coli cells (of WT tat or Δtat background) in LB media.
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Protein expression was induced at T = 0 hr with 1mM IPTG. OD600
values were recorded at 15‐min intervals for the first 3 hr, and then
at 1‐hr intervals following this.
2.10 | TMAO reductase activity assay (TorA assay)
Cells were grown in LB media supplemented with glycerol (0.5% v/v),
trimethylamine N‐oxide (TMAO; 0.4% w/v), and sodium molybdate
(1 µM; LB‐GT) and fractionated as described in Section 2.2. Serial
dilutions of the cytoplasmic and periplasmic fractions (1, 1/10, 1/100,
and 1/100) were run on native 12% polyacrylamide gels and the
presence of TMAO reductase was detected using a protocol adapted
from Silvestro, Pommier, and Giordano (1988). Immediately following
native PAGE, the gel was placed in a nitrogen‐saturated container
and covered with 100mM potassium phosphate and 0.25% w/v
methyl viologen (buffer saturated with nitrogen gas). The gel was
stained blue by adding freshly prepared sodium dithionate (0.1% w/v
in 10mM NaOH) and incubating for 30–60min until the gel was
saturated blue. Gels were then transferred to another container
(saturated with nitrogen gas), and covered with 100mM potassium
phosphate and 40mM TMAO (buffer saturated with nitrogen gas)
until white bands could be visualized. Photos were taken on a
handheld camera as bands appeared.
2.11 | Light microscopy of E. coli cells
To check for a chain‐forming phenotype of E. coli cells overexpressing
either TorA‐hGH or TorA‐A39L‐hGH, cells were visualized under a
Zeiss Primostar light microscope at X400 magnification.
3 | RESULTS
3.1 | TorA‐hGH is exported efficiently by the TAT
system
hGH was expressed with a N‐terminal TorA signal peptide that contains
several features typical of a Tat signal peptide (hereafter referred to as
TorA‐hGH). These include an N‐terminal domain, a hydrophobic core
region and a polar C‐terminal domain ending with an Ala–Xaa–Ala
consensus motif (Figure 1). It is this signal peptide that targets hGH, and
other proteins, to the inner membrane of E. coli for efficient export into
the periplasm by the Tat machinery (Ren et al., 2013).
(Alanen et al., 2015) showed that hGH can be exported by Tat and
subsequently acquire its disulfide bonds in the periplasm. The aim of this
study was to gain a more detailed insight into the export of this
biopharmaceutical in E. coli, and in particular to directly visualize the
location of the exported protein. We initially used standard export
assays to examine the export of TorA‐hGH in WT MC4100 E. coli cells
expressing native levels of Tat machinery. At certain time points, up
until 2 hr after the induction of the plasmid, cells were fractionated to
generate cytoplasm (C), periplasm (P), and membrane and insoluble (MI)
samples which were analyzed by SDS‐PAGE and immunoblotting.
Immunoblotting against hGH protein showed two forms of hGH are
produced in whole cell fractions: a 27 kDa precursor protein and 22 kDa
mature protein (Figures 2,4). Some nonspecific bands are also observed.
Export assays demonstrated that Tat‐mediated transport of
TorA‐hGH occurs soon after the induction since, after 1 hr, mature
hGH is present in the periplasm. There is a minimal amount of
precursor protein present in the cytoplasmic fraction, which has also
been observed in previous analyses of Tat‐dependent export of TorA‐
hGH (Ren et al., 2013). Therefore, the lack of cytoplasmic precursor
protein in this study could be due to the quick turnover of the
substrate from the cytoplasm to the periplasm, or due to proteolytic
cleavage of the precursor protein (Figure 2). Quick turnover of the
precursor hGH would also explain the lack and/or minimal amount of
precursor hGH present at the membrane up until 1 hr 30. Only at
later time points (1 hr 45 and 2 hr) do we see a substantial increase in
precursor at the membrane, which is consistent with increased
production of hGH precursor/Tat substrate.
To confirm that the export of TorA‐hGH is via Tat, an identical
export assay was performed in E. coli cells lacking Tat machinery
(ΔtatABCDE; hereafter denoted Δtat). The lack of mature hGH in the
periplasm of these control cells, at any time point, confirms Tat‐
dependent export of hGH into the periplasm in WT E. coli (Figure 3).
3.2 | Substitution of the −1 position of the signal
peptide blocks maturation of TorA‐hGH
It has previously been shown that the nature of the amino acid side






F IGURE 1 Structure of the TorA signal peptide and the TorA‐A39L variant. Primary structure of the 42‐residue signal peptide of E. coli TorA.
The consensus motif is highlighted in bold (twin‐arginine motif, dotted underline), and the peptidase cleavage site is underlined. The terminal,
alanine residue at position 39 (highlighted), was substituted by leucine to generate the TorA‐A39L variant
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F IGURE 2 Export assay of Tat substrate (TorA‐hGH) into the periplasm of E. coli. Western blot to detect the presence of hGH in E. coli.
Postinduction with 1mM IPTG E. coli cells overexpressing hGH fused to a TorA signal peptide (TorA‐hGH) were grown at 37°C for 2 hr. During
this time, cells were periodically harvested, normalized for OD600 = 10 and subsequently fractionated to periplasm (P), cytoplasm (C), and
membrane/insoluble fractions (MI) fractions. Each fraction was examined for the presence of hGH by immunoblotting with anti‐hGH antibody.
Results show there is a good level of export from as early as 1 hr after induction, shown by the presence of mature hGH (22 kDa) in the
periplasm. At each time point there is a lack of precursor (27 kDa) TorA‐hGH (i.e., Tat substrate) in the cytoplasmic fractions, indicating the
substrate is either degraded or forming inclusion bodies in the cell. From 1 hr 45min onwards, there is a consistent level of precursor TorA‐hGH
in the membrane fraction of the E. coli cells suggesting to the formation of inclusion bodies. hGH, human growth hormone; IPTG, isopropyl
β‐D‐1‐thiogalactopyranoside
F IGURE 3 Export assay of TorA‐hGH into the periplasm of E. coli cells lacking expression of Tat machinery western blot to detect the
presence of hGH in E. coli. Postinduction with 1mM IPTG E. coli cells overexpressing hGH fused to a TorA signal peptide (TorA‐hGH) and lacking
expression of Tat machinery, that is, Δtat were grown at 37°C for 2 hr. During this time, cells were periodically harvested, normalized for
OD600 = 10 and subsequently fractionated to periplasm (P), cytoplasm (C), and membrane/insoluble fractions (MI) fractions. Each fraction was
examined for the presence of hGH by immunoblotting with anti‐hGH antibody. Results show that mature hGH (22 kDa) is present in the
cytoplasm from very early on (1 hr). Precursor hGH (27 kDa) expression increases at 1 hr 30, and there is no hGH present in the MI fraction at
all time points tested. hGH, human growth hormone; IPTG, isopropyl β‐D‐1‐thiogalactopyranoside
F IGURE 4 Export assay of a noncleavable Tat substrate (TorA‐A39L‐hGH) into the periplasm of E. coli. Western blot to detect the presence
of noncleavable hGH in E. coli. Postinduction with 1mM IPTG E. coli cells overexpressing hGH fused to a noncleavable TorA signal peptide
(TorA‐A39L‐hGH) were grown at 37°C for 2 hr. During this time, cells were periodically harvested, normalized for OD600 = 10 and subsequently
fractionated to periplasm (P), cytoplasm (C), and membrane/insoluble (MI) fractions. Each fraction was examined for the presence of hGH by
immunoblotting with anti‐hGH antibody. A lack of hGH protein in the periplasm of any time point confirms that the Tat substrate is
noncleavable and thus remains in the inner membrane fraction. hGH is degraded in the cytoplasm from as early as 1 hr indicated by the mature
sized hGH (22 kDa). This is degraded completely by 1 hr 30min. From 1 hr 15min onwards there is a consistent level of precursor TorA‐hGH
(27 kDa) in the membrane fraction of the E. coli. hGH, human growth hormone; IPTG, isopropyl β‐D‐1‐thiogalactopyranoside
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of the signal peptide) is essential for efficient maturation of a Tat
precursor protein (Ren et al., 2013). The maturation enzyme, leader
peptidase, will only tolerate a short chain residue such as alanine at
this position. Substitution of the alanine residue at the −1 position of
the signal peptide by leucine completely blocked maturation of a
native Tat substrate, YedY, with the protein remaining membrane‐
bound and its mature domain exposed to the periplasm (Ren
et al., 2013).
To test whether the same mutation blocks maturation of hGH—a
biotechnologically relevant, heterologous Tat substrate—export
assays were conducted as in Section 3.1, with the −1 alanine residue
in the TorA signal peptide of TorA‐hGH substituted with leucine
(generating TorA‐A39L‐hGH).
Consistent with the findings of (Alanen et al., 2015; Ren et al., 2013),
the precursor protein was not processed to any significant degree and is
found almost exclusively in the membrane fraction as a precursor
protein (Figure 4; 1 hr 15 time point onwards). As seen with the WT
precursor, mature hGH was detected in the cytoplasm from an early
time point (1 hr), which most likely represents proteolytic cleavage of
the signal peptide, as observed previously (Alanen et al., 2015).
To confirm that the results of our export assays are not affected by
inaccurate fractionation of E. coli, we immunoblotted for the presence
of maltose binding protein and LacI in the cytoplasm, membrane and
insoluble, and periplasm fractions (Supporting Information Figure S1).
LacI (which can be sequestered to the inner membrane as a means of
gene regulation in bacteria [Görke, Reinhardt, & Rak, 2005]) was not
detected in the periplasm (Supporting Information Figure S1, top
panel), confirming the successful isolation of the periplasmic region
from the cytoplasmic and membrane/insoluble fractions with no/
negligible contamination. Detection of maltose binding protein in all
three fractions of E. coli (particularly with the least amount in the
membrane and insoluble fraction; Supporting Information Figure S1,
bottom panel) is consistent with the transient export of this protein
into the periplasm via the Sec translocase machinery. Together, these
data confirm the accurate and reproducible fractionation of E. coli cells
used in this study.
3.2.1 | Expression of TorA‐A39L‐hGH does not
affect E. coli viability
To confirm that the mutated TorA signal peptide (A39L) does not cause
permanent blockage of the Tat machinery, which would otherwise cause
a problem with cell viability, a growth curve of E. coli cells (overexpressing
either TorA‐hGH or TorA‐A39L‐hGH) was conducted. Results show that
the growth profile of E. coli is near‐identical when overexpressing either
TorA‐hGH or TorA‐A39L‐hGH (Supporting Information Figure S2).
3.2.2 | Expression of TorA‐A39L‐hGH does not
block translocation of TMAO reductase
It is important to understand if normal functioning of the twin‐
arginine translocase occurs in cells expressing a substrate that is
blocked in the membrane. To this end, we used an assay for a native
Tat substrate TorA (TMAO reductase). TorA is a large (90 kDa),
cofactor binding enzyme of E. coli that is transported to the periplasm
via the Tat system after binding two molybdenum guanine dinucleo-
tide (MGD) molecules in the cytoplasm. It is responsible for the
reduction of the terminal electron acceptor TMAO to trimethylamine
(Barrett & Kwan, 1985). TorA has enzymatic activity in both the
cytoplasm and the periplasm (Sargent et al., 1998) and is, therefore,
an ideal candidate to show whether translocation is blocked.
To conduct the assay cells are grown in LB‐GT media and either
TorA‐hGH or TorA‐A39L‐hGH were expressed for 3 hr. The cells were
then fractionated into cytoplasm, membrane, and periplasm, and serial
dilutions of cytoplasm and periplasm were separated on native
polyacrylamide gels. The gels were stained with reduced methyl
viologen before being incubated with TMAO in an anaerobic environ-
ment. The appearance of white bands on the dark background indicates
the activity, and thus localization of TMAO reductase through the
coupled reduction of TMAO and oxidation of methyl viologen. The
results of the TMAO reductase assay are shown in Figure 5. In cells
expressing TorA‐hGH TMAO reductase activity can be seen in both the
cytoplasm and periplasm indicating normal functioning of the Tat
system. The lower panel shows TMAO reductase is also active in the
periplasm of cells expressing TorA‐A39L‐hGH confirming the mutation
that blocks this substrate in the membrane does not affect the ability of
the Tat system to translocate other Tat‐dependent proteins.
3.2.3 | Expression of TorA‐A39L‐hGH does not
cause a chain‐forming phenotype
Previous studies have shown that inactivation of the E. coli Tat pathway
causes defects in cell division. This manifests as the formation of cell‐
F IGURE 5 The endogenous Tat substrate TMAO reductase is
correctly localized in cells expressing a noncleavable Tat substrate
(TorA‐A39‐hGH). E. coli MC4100 were grown for 3 hr in LB‐GT
media expressing either TorA‐hGH (top panel) or TorA‐A39L‐hGH
(bottom panel) and then fractionated in cytoplasm and periplasm.
These fractions were serially diluted (decreasing concentration
indicated by slope) and run on native PAGE. Gels were then stained
for TMAO reductase activity. For cells expressing TorA‐hGH (top
panel), TMAO reductase activity can be seen in both the cytoplasm
and periplasm. hGH, human growth hormone; PAGE, polyacrylamide
gel electrophoresis; TMAO, trimethylamine N‐oxide
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chains, visible under a light microscope (Stanley, Findlay, Berks, &
Palmer, 2001). These chains, up to 10‐cells long, are likely caused by the
inability to correctly localize the native Tat substrates AmiA and AmiC.
AmiA and AmiC are amidases involved in murein cleavage during cell
division and naturally reside in the periplasm. Empty MC4100 cells
expressing either TorA‐hGH or TorA‐A39L‐hGH, and MC4100 Δtat
were grown aerobically for 3 hr. Images representative of these cultures
is shown in Figure 6. Empty MC4100 cells are clearly shown as
individual cells (Figure 6a). For contrast, panel B of Figure 6 shows “cell
chains” that are formed when the Tat machinery is inhibited (or in this
case removed). Panels C and D show cultures expressing TorA‐hGH and
TorA‐A39L‐hGH, respectively, and these display a phenotype like that
of the empty MC4100 (Figure 6a). These images help to confirm the Tat
substrate blocked in the membrane does not hinder the export of other
Tat‐targeted substrates.
3.3 | Direct visualization of a biotherapeutic, hGH,
in E. coli
3.3.1 | Visualization of TorA‐hGH
Harnessing of industrial microorganisms, such as E. coli, for the
production of desired products is reliant on the efficient performance
of these “cell factories.” As such, numerous factors serve as important
indicators of platform fitness including: protein localization and
distribution, and cellular morphology. Previous studies that have
analyzed the export of biotechnologically relevant proteins by the Tat
machinery have primarily used biochemical approaches (Karlsson
et al., 2012; Ren et al., 2013), yet direct visualization of the
microorganism, in this case E. coli, could provide novel insight into
the export of such substrates. In this study, we analyzed the location of
TorA‐hGH to test whether the exported protein is indeed randomly
distributed in the periplasm, and focused particular attention on the
noncleavable A39L‐hGH to determine whether the protein is
uniformly distributed in the inner membrane.
To do this, E. coli cells overexpressing TorA‐hGH or TorA‐A39L‐hGH
were fixed and stained. 2D sections of individual E. coli cells were then
cut, immunolabelled and finally examined for the presence of gold
particles. Use of antibodies specific to hGH avoids the use of (potentially
large) affinity tags, and thus permits direct protein detection. Gold
particles were classified according to their location, and for the present
study, a gold particle found within 25 nm of the inner membrane was
defined as being located at the inner membrane. Our aim was to achieve
unambiguous identification of the hGH protein in the inner membrane
through immunogold labeling of E. coli cells overexpressing TorA‐hGH
or TorA‐A39L‐hGH. To do this, the level of nonspecific antibody labeling
was assessed through comparison of hGH‐overexpressing cells with
MC4100 E. coli cells that did not overexpress any recombinant protein.
Figure 7 shows representative images of TorA‐hGH‐overexpres-
sing cells that were immunogold labeled with anti‐hGH. These cells
exhibit a pattern of gold labeling that is predominantly around the
periphery of the cell. This was confirmed at increased magnification,
as in Figures 6 (bottom row), where the gold particles could be seen
to reside within 25 nm of the inner membrane of the cell wall. Given
that the bulk of the protein has been shown to be present in
periplasmic fractions using export assays (Figure 2), we conclude that
these particles are indeed located in the periplasm of the cells. A
smaller number of particles were present in the cytoplasm. Magnified
images of these cells, with closeups of individual gold particles, can
also be seen in Supporting Information Figure S3.
Analysis of E. coli cells that did not express TorA‐hGH (represen-
tative images shown in Supporting Information Figure S4), showed the
presence of only a few gold particles in the cytoplasmic and
membranous regions. These data indicate that the antibody is able
to detect hGH with a high degree of specificity. As further controls,
TorA‐hGH‐expressing cells were immunolabelled with the primary
antibody omitted (Supporting Information Figure S5, a and b), and the
TEM analysis showed that these cells lacked any gold binding
confirming that nonspecific binding seen in E. coli cells not over-
expressing any recombinant protein was attributable to the primary
antibody. Finally, the same cell type was immunolabelled with a gold‐
conjugated secondary antibody directed towards a different animal
species (Supporting Information Figure S5, c and d). The TEM analysis
showed only unlabeled E. coli cells, confirming that the cells do not
have a nonspecific attraction for gold particles.
To quantitate the degree of specific labeling, raw gold counts were
collected from 200 randomly sampled, immunolabelled E. coli with or
without the overexpression of TorA‐hGH, and the gold particles were
assigned to either the cytoplasmic or inner membrane/periplasm
compartments. Quantification of the gold particles (Figure 8) shows that
the average number of gold particles per compartment in TorA‐hGH‐
F IGURE 6 Expression of a noncleavable Tat substrate (TorA‐A39L‐hGH) does not block translocation AmiA and AmiC. Left to right:
Microscope images of empty MC4100, empty MC4100 Δtat, MC4100 TorA‐hGH, and MC4100 TorA‐A39L‐hGH. The Δtat image clearly shows
the chain‐forming phenotype. Images of cells expressing TorA‐hGH and TorA‐A39L‐hGH resemble that of the empty wild‐type. Scale is bar
20 μM. X400 magnification. hGH, human growth hormone
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F IGURE 7 Electron micrographs of E. coli cells, overexpressing TorA‐hGH (WT precursor), immunogold labeled following primary antibody
detection against hGH protein. Ultrathin sections of E. coli cells overexpressing TorA‐hGH (WT precursor) were immunolabelled using a
polyclonal antibody raised against hGH (shown in rows 1–3, with row 4 showing closeups of individual gold particles from row 3). At 1 hr 45min
after induction, hGH was found to exhibit a random distribution in the inner membrane (yellow arrows) and was also present in the cytoplasm
(red arrows). Images were taken on a JEOL 2010F at X15,000 magnification. Scale bar = 200 nm. hGH, human growth hormone; WT, wild type
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overexpressing cells was 1.92 per cell ( ± 0.41 gold) in the cytoplasm and
4.29 per cell ( ± 0.37 gold) in the inner membrane, whereas E. coli cells
lacking overexpression of TorA‐hGH bound 0.86 per cell in the cytoplasm
( ± 0.19 gold) and 0.46 ( ± 0.15 gold) in the membrane, respectively. The
labeling of membrane‐bound TorA‐hGH is thus highly specific, with the
inner membrane/periplasm of TorA‐hGH‐overexpressing cells containing
9.42‐fold more gold particles than the same membrane in E. coli cells that
lack overexpression of TorA‐hGH. To confirm a statistical independence
in immunogold labeling between these cells at the cytoplasm and inner
membrane, χ2 analysis of the raw gold count data was conducted. For a
total χ2 value of 111.2 and 1 degree of freedom, p was <0.005. This
confirms that the gold labeling distributions between the two cell types
are significantly different.
Analysis of the distribution of gold particles in the cytoplasm
shows the presence of 1.92 and 0.86 particles in the TorA‐hGH‐
overexpressing and non‐hGH expressing E. coli cells, respectively.
Since the number of gold particles in E. coli cells that lack
overexpression of hGH represents nonspecific binding, and assuming
that the level of nonspecific binding in the two cell types is the same,
this indicates that TorA‐hGH‐overexpressing cells contain an average
of one gold particle per cell in the cytoplasm, which is considerably
lower than the 3.8 gold particles per cell in the inner membrane/
periplasm region. This difference is consistent with the amount of
hGH in the cytoplasmic fraction compared with the membranous
compartment of E. coli determined by export assays, which revealed
that at 1 hr 45min after induction, there is considerably more hGH
present in the membrane fraction compared with the cytoplasm
(Figure 2). Our immunolabelling approach thus provides highly
specific detection of hGH in both the cytoplasmic and membrane
fractions of E. coli.
Immunogold labeling of TorA‐hGH showed this protein is
randomly distributed within the E. coli periplasm and cytoplasm,
with no evidence for a preferential localization at the poles or
elsewhere (Figure 7, yellow and red arrows, respectively). This is
the first time that a heterologous Tat substrate has been directly
visualized after export to the periplasm, and these observations
are consistent with the efficient production of hGH in our E. coli
cells.
3.3.2 | Visualization of noncleavable TorA‐hGH
To investigate whether a similar distribution and/or localization occurs
for the mutated TorA‐hGH construct, (TorA‐A39L‐hGH), we immuno-
gold labeled E. coli cells overexpressing TorA‐A39L‐hGH to detect the
presence of hGH. Analysis of the localization and distribution of gold
particles showed that similar to the WT precursor (TorA‐hGH, Section
3.3.1), TorA‐A39L‐hGH exhibits a random distribution in the cyto-
plasm (red arrows) and a uniform distribution in the inner membrane
(yellow arrows) of the E. coli cell (Figure 9). This was confirmed at
higher magnifications, as in Figures 8 (bottom row) and Supporting
Information Figure S6. Therefore, in addition to biochemical export
assays (Figure 4) which showed a lack of TorA‐A39L‐hGH in the
F IGURE 8 Quantitative analysis of raw gold counts of E. coli cells immunogold labeled with primary antibody detection against TorA‐hGH
protein. E. coli cells overexpressing TorA‐hGH were immunolabelled using a primary antibody against the hGH protein. Controls were E. coli cells
that lacked expression of hGH protein (labeled (-) hGH). Raw gold counts were taken from 200 randomly imaged E. coli from two separate resin
blocks. Gold was assigned to either “membrane + periplasm” (labeled membrane) or cytoplasm compartment. The approximate numbers of gold
particles at the cytoplasm and membrane fraction of each cell were calculated for each cell type. There was 2.2x more gold in the cytoplasm
(line‐patterned) of hGH expressing cells versus those lacking hGH expression. There was 9.43x more gold in the membrane (dotted pattern) of
hGH expressing cells versus those lacking hGH expression. Error bars: CI of 2x SE. The labeling of hGH between the two cell types is statistically
significant (indicated by ++). hGH, human growth hormone
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F IGURE 9 Electron micrographs of E. coli cells, overexpressing TorA‐hGH (mutant precursor), immunogold labeled following primary
antibody detection against hGH protein. Ultrathin sections of E. coli cells overexpressing TorA‐hGH (mutant precursor) were immunolabelled
using a polyclonal antibody raised against hGH (shown in rows 1–3, with row 4 showing closeups of individual gold particles from row 3). At 1 hr
45min after induction, hGH was found to exhibit a random distribution in the inner membrane (yellow arrows) and was also present in the
cytoplasm (red arrows). Images were taken on a JEOL 2010F at X15,000 magnification. Scale bar = 200 nm. hGH, human growth hormone
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periplasm, these EM data provide direct evidence that an unprocessed
Tat precursor remains membrane‐associated despite being unable to
undergo cleavage by signal peptidases in the periplasm.
4 | DISCUSSION
The twin‐arginine translocase offers the potential for the biotechnol-
ogy industry owing to its ability to transport fully‐folded proteins into
the periplasm of E. coli. Initial studies confirmed the capability of the
Tat system to transport a model heterologous protein to a high yield
(Matos et al., 2012), and more recent data has shown that substrates
are not limited to GFP with Tat being able to transport hGH, scFv,
and interferon α2b (Alanen et al., 2015; Browning et al., 2017).
Furthermore, it has also been shown that it is possible to anchor a
Tat substrate in the inner membrane of E. coli with the mature
domain of the protein facing the periplasmic side of the membrane
(Karlsson et al., 2012; Ren et al., 2013). Combined, these data reveal
a novel potential for the Tat system in producing single‐span
membrane proteins in E. coli.
Anchoring of heterologous Tat substrates in the inner membrane
has previously occurred via the addition of extra amino acid residues
to the protein sequence (Karlsson et al., 2012). However, this study
has shown that only a single substitution mutation in the signal
peptidase cleavage site of a TorA signal peptide, fused to hGH,
resulted in the precursor protein being “stalled” at the inner
membrane, with no alterations to the mature protein. The previous
studies by (Karlsson et al., 2012) and (Ren et al., 2013) showed that
cleavage by leader peptidase occurs only after transfer of the mature
protein to the periplasm, and given that hGH is exported by Tat in an
extremely efficient manner, it is to be expected that the mature hGH
protein will be similarly positioned on the periplasmic face of the
inner membrane. This could be confirmed using a structural biology
approach whereby E. coli spheroblasts (overexpressing TorA‐hGH or
TorA‐A39L‐hGH) are immunogold labeled specifically for hGH and
subsequently visualized by SEM. This would allow visualization of the
periplasmic side of the inner membrane with the hGH‐bound
immunogold, and confirm the topology of the mature hGH as
periplasmically exposed.
In summary, a combination of biochemical export assays and
imaging approaches were used in this study to investigate the
temporal expression of TorA‐hGH and TorA‐A39L‐hGH in E. coli and
to determine whether they were transported via Tat machinery. Our
data serves as a proof‐of‐concept study where we have demonstrated
the Tat‐dependent transport of TorA‐hGH into the periplasm and
most importantly, the stable expression of TorA‐A39L‐hGH at the
inner membrane. We propose that this novel methodology could be
developed for the targeting, transport, and display of other industrially
important single‐span membrane proteins at the inner membrane of E.
coli via the Tat machinery. Having shown the potential of this system
for the display of one industrially relevant target protein, hGH, we
acknowledge that further studies with a more tractable substrate
protein would be of interest to enable activity on the inner membrane
to be determined. This further work would develop our novel
methodology and fully explore its application for other targets.
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